Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy is on hold due to safety issues. An FDA official warns the path to market approval is fraught with challenges, especially after patient deaths linked to liver injuries.
In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
Sarepta Therapeutics is under fire as another patient succumbs to acute liver failure linked to its gene therapy trial for muscular dystrophy, adding to the recent deaths of two teenage boys.
Robert F. Kennedy Jr. proposes expanding access to experimental medical treatments, acknowledging potential risks from unlicensed providers. Is this a step forward or a danger to public health?
A cautionary tale from a geriatrician reveals the risks of cannabis gummies for seniors. A 76-year-old's experience highlights the importance of proper dosage and awareness of drug interactions.
Infections from the drug-resistant fungus Candida auris are rising alarmingly in U.S. hospitals, posing a significant risk to already sick patients. Despite being manageable for healthy individuals, its resistance to treatments makes it a growing concern in healthcare settings.
In a shocking turn of events, more than 500 mpox patients have fled healthcare facilities in eastern DR Congo due to escalating violence from M23 rebels. The Africa CDC warns of a potential outbreak as missing patients risk spreading the disease, which has already claimed numerous lives.
